Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + Erlotinib as First-line Therapy for Advanced Non-squamous NSCLC
NCT00585377Phase 2Completed
- Sponsor
- University of Utah
- Start
- Aug 2007
- Primary completion
- May 2013
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, erlotinib in non-small cell lung cancer (NSCLC), sponsored by University of Utah. Started Aug 2007; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00585377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00585377.